Oxymorphone
Opioid analgesic drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about oxymorphone?
Summarize this article for a 10 year old
Oxymorphone (sold under the brand names Numorphan and Opana among others) is a highly potent opioid analgesic indicated for treatment of severe pain. Pain relief after injection begins after about 5–10 minutes, after oral administration it begins after about 30 minutes, and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets.[5] The elimination half-life of oxymorphone is much faster intravenously, and as such, the drug is most commonly used orally.[6] Like oxycodone, which metabolizes to oxymorphone, oxymorphone has a high potential to be abused.[7]
Clinical data | |
---|---|
Trade names | Numorphan, Numorphone, Opana, others |
Other names | 14-Hydroxydihydromorphinone |
AHFS/Drugs.com | Monograph |
MedlinePlus | a610022 |
License data |
|
Dependence liability | High |
Addiction liability | High |
Routes of administration | By mouth, buccal, sublingual, intranasal, intravenous, epidural, subcutaneous, intramuscular |
Drug class | Opioid |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | by mouth: 10% Buccal: 28% Sublingual: 37.5% Intranasal: 43%[3] IV, IM & IT: 100%[4] |
Protein binding | 10%[4] |
Metabolism | Liver (CYP3A4, glucuronidation)[4] |
Elimination half-life | 7–9 hours[4] |
Duration of action | Duration of action: 6–8 hours orally, 4–6 hrs parenteral |
Excretion | Urine, feces[4] |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.873 |
Chemical and physical data | |
Formula | C17H19NO4 |
Molar mass | 301.342 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
It was developed in Germany in 1914. It was patented in 1955 and approved for medical use in 1959.[8] In June 2017 the FDA asked Endo Pharmaceuticals to remove its product from the US market.[9] This was in part due to the opioid epidemic in the US, and the fact that a 2012 reformulation failed to stop illicit injection of the drug. Endo responded by voluntarily removing Opana ER from the market a month later.[10] Generic versions of extended-release oxymorphone, such as those manufactured by Amneal Pharmaceuticals, are still available in the US.[11]